Idiopathic Intracranial Hypertension: A Systematic Analysis of Transverse Sinus Stenting

Mohamed S. Teleb a Matthew E. Cziep a Marc A. Lazzaro a–c Ayman Gheith a Kaiz Asif a Bernd Remler a, d Osama O. Zaidat a–c

Departments of a Neurology, b Neurosurgery, c Radiology and d Ophthalmology, Medical College of Wisconsin/Froedtert Hospital, Milwaukee, Wisc., USA

Key Words
Idiopathic intracranial hypertension · Venous stenosis · Pseudotumor cerebri · Angiography · Stenosis · Stenting · Sinus stenting

Abstract
Background: Idiopathic intracranial hypertension (IIH) is a disorder characterized by signs and symptoms of increased intracranial pressure without structural cause seen on conventional imaging. Hallmark treatment after failed medical management has been CSF shunting or optic nerve fenestration with the objective of preserving vision. Recently, there have been multiple case reports and case series on dural sinus stenting for this disorder. Objective: We aim to review all published cases and case series of dural sinus stenting for IIH, with analysis of patients’ presenting symptoms, objective findings (CSF pressures, papilledema, pressure gradients across dural sinuses), follow-up of objective findings, and complications. Methods: A Medline search was performed to identify studies meeting prespecified criteria of a case report or case series of patients treated with dural sinus stent placement for IIH. The papers were reviewed and data were extracted. Results: A total of 22 studies were identified, of which 19 studies (including a total of 207 patients) met the criteria and were included in the analysis. Only three major complications related to the procedure were identified. Headaches resolved or improved in 81% of patients. Papilledema improved in 90% of cases (172 of 189 patients). Sinus pressure decreased from an average of 30.3 to 15 mm Hg. Sinus pressure gradient decreased from 18.5 mm Hg (n = 185) to 3.2 mm Hg (n = 172). Stenting had an overall symptom improvement rate of 87%. Conclusion: Although all published case reports and case series...
are nonrandomized, the low complication and high symptom improvement rate make dural sinus stenting for IIH a potential alternative surgical treatment. Standardized patient selection and randomization trials or registry are warranted.

Introduction

Idiopathic intracranial hypertension (IIH) is a syndrome of increased intracranial pressure (ICP) of unknown etiology. Patients present with symptoms of increased ICP including headache, tinnitus, papilledema, visual defects, nausea, and cranial nerve palsies (most commonly cranial nerve 6, although others have been reported). If not recognized early and treated, IIH can lead to blindness. The hallmark features of this disease are symptoms of increased ICP without conventional and radiological abnormalities [1, 2]. Many mechanisms have been proposed, including parenchymal edema, increased cerebral blood volume, venous outflow obstruction, and obesity-related increased central venous pressure, but no consensus on the pathophysiological causes exists [3]. Venous stent placement as a treatment option for IIH is a relatively new treatment modality introduced a decade ago. Retrospective, nonrandomized literature has demonstrated symptom improvement [4–10]. In a recent review, not all issues have been addressed [11]; therefore, with this study, we wanted to add a more comprehensive review to the literature. We aimed to investigate all case reports and case series that had been published on this treatment technique for IIH with the intention of looking at patients’ presenting symptoms, complications from procedures, recurrence, technical aspects, and outcomes.

Methods

A Medline search was performed using different combinations of the following terms: ‘pseudotumor cerebri venous stent placement’ and ‘idiopathic intracranial hypertension venous stent’. A similar search was run in Google Scholar and PubMed. Our search was limited to the English language and articles with an English translation. Only those reports designed as a case report or case series of patients treated with dural sinus stent placement for IIH were included. Review papers were excluded. Our search was limited to the last 15 years (1998 to May 2013). Studies with likely consecutive inclusion of the same patient(s), inadequate or irrelevant data were excluded. We also included a total of 22 patients from our institution.

The papers were reviewed and data were extracted. An Excel spreadsheet with objective values was created. Basic statistical methods for mean, maximum and minimum values as well as paired Student’s t tests were conducted to evaluate the data sets before and after treatment when applicable. Where data were not available in all studies, the smaller subgroups were analyzed. The following website was used for the t test calculations: http://graphpad.com/quickcalcs/ttest2/.

Results

A total of 22 studies were identified, of which 19 met the prespecified criteria [4–10, 12–23]. A total of 207 affected individuals were treated for IIH with venous sinus stent placement. All individuals expressed some symptoms of IIH, the most prominent being...
headache and papilledema, while fewer had vision obscurations or tinnitus. Table 1 shows the most common symptoms per case series.

**Selection**

Unfortunately, selection criteria were not uniform. Not all patients had papilledema or visual disturbances as demonstrated above. The only universal finding was elevated ICP and headache. Most large series only stented patients with a gradient of ≥10 mm Hg [5–7, 9, 14, 18, 19], with three exceptions: Ahmed et al. [12] had stenting criteria of ≥8 mm Hg, Radvany et al. [8] used ≥4 mm Hg, and Albuquerque et al. [13] did not report pressure gradients. Fields et al. [6] only stented patients whose dominant sinus had stenosis. All series also included patients who had failed medical or surgical treatment.

**Headache**

Of the 207 patients, 192 presented with headaches; the duration of these symptoms ranged from a few weeks to several years. Following treatment, headaches completely resolved in 72 patients, improved in 83, remained the same in 35, and became worse in 2 patients. This equates to an improvement rate of 81%. Long-term durability of headache resolution was not reported (table 1).

**Papilledema**

Of the 19 studies, 18 reported on papilledema and included 189 patients. A total of 172 of 189 (90%) patients presented with papilledema. After treatment, the papilledema resolved in 126 patients, improved in 23, and remained unchanged in 22. The improvement rate after treatment of papilledema was 87%. Unfortunately, the exact time course for resolution or

---

**Table 1. Overview of dural sinus stenting cases: major reported symptoms and their outcomes**

<table>
<thead>
<tr>
<th>First author</th>
<th>Cases, f/m</th>
<th>Headache</th>
<th>Papilledema</th>
<th>Visual problems</th>
<th>Follow-up (mean), months</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>resolved/</td>
<td>no Δ</td>
<td>resolved/</td>
<td>no Δ</td>
</tr>
<tr>
<td>Ahmed [12], 2011</td>
<td>47/5</td>
<td>40</td>
<td>3</td>
<td>46</td>
<td>0</td>
</tr>
<tr>
<td>Albuquerque [13], 2011</td>
<td>15/3</td>
<td>16</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Arac [20], 2009</td>
<td>1/0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Bussière [14], 2010</td>
<td>10/0</td>
<td>10</td>
<td>0</td>
<td>9</td>
<td>0</td>
</tr>
<tr>
<td>Donnet [9], 2008</td>
<td>8/2</td>
<td>8</td>
<td>2</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>Fields [6], 2012</td>
<td>15/0</td>
<td>10</td>
<td>4</td>
<td>15</td>
<td>0</td>
</tr>
<tr>
<td>He [10], 2012</td>
<td>24</td>
<td>16</td>
<td>8</td>
<td>10</td>
<td>14</td>
</tr>
<tr>
<td>Higgins [5], 2003</td>
<td>12/0</td>
<td>7</td>
<td>5</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Higgins [4], 2002</td>
<td>1/0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Khalia [21], 2010</td>
<td>18/4</td>
<td>18</td>
<td>4</td>
<td>16</td>
<td>0</td>
</tr>
<tr>
<td>Kumpe [7], 2012</td>
<td>12/6</td>
<td>10</td>
<td>2</td>
<td>16</td>
<td>2</td>
</tr>
<tr>
<td>Lazzaro [19], 2012</td>
<td>3/0</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Ogungbo [15], 2003</td>
<td>1/0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Owler [18], 2003</td>
<td>3/1</td>
<td>4</td>
<td>0</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Paquet [17], 2008</td>
<td>1/0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Rajpal [16], 2005</td>
<td>0/1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Radvany [8], 2013</td>
<td>11/1</td>
<td>7</td>
<td>5</td>
<td>11</td>
<td>1</td>
</tr>
<tr>
<td>Teleb [23], 2012</td>
<td>1/0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Zheng [22], 2010</td>
<td>1/0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>

Δ = Change.

*Case series presented in abstract form at the 2010 Annual Meeting of the American Academy of Neurology, Poster P05.284.*
improvement is not reported; however, most report that eye exam was done during the first follow-up assessment which was performed after weeks to months later. Radvany et al.'s [8] study specifically stated that eye exams where carried out between 6 and 12 weeks (table 1).

**Visual Obscurations**
Sixteen studies, including 176 of 207 (85%) patients, reported on visual obscurations. Of the 176 individuals, 156 were found to have visual disturbances (acuity, field loss, diplopia, etc.). Treatment completely resolved visual disturbances or improved vision in 116 patients and halted deterioration in 36. In 4 patients, vision deteriorated after stent placement. In preventing visual problems from progressively becoming worse, the success rate was 97%, but in improving or resolving visual disturbances, the success rate was 74% (table 1).

**Tinnitus**
Only 10 of 19 studies (n = 153) reported on patients with tinnitus. Sixty-five patients (42%) reported suffering from tinnitus. Following stenting, 29 patients reported resolution, 33 stated improvement, and 3 reported no change. Treatment showed a 95% improvement of tinnitus.

**CSF Pressure**
Not all studies reported explicit individual CSF opening pressures before and after endovascular therapy of IIH. For those that did, almost all only reported the preprocedure opening pressure (15 of 19). The mean CSF opening pressure before treatment was 36.3 cm H$_2$O with a range of 25–73 cm H$_2$O (n = 100) [4, 5, 7–9, 15–18, 22, 23]. After stent placement, six studies had a mean CSF opening pressure of 19.2 cm H$_2$O with a range of 9–26 cm H$_2$O (n = 20) [9, 15, 18, 22]. The mean pressure decreased by 16.3 cm H$_2$O (table 2).

**Sinus Pressure**
Sinus pressure before treatment had a mean of 30.3 mm Hg (15–94 mm Hg) reported in 14 of 19 studies (n = 107) [4, 5, 9, 12, 15–18, 22, 23]. Only seven studies reported pressure before and after treatment (n = 111) [12, 18, 23]. After stenting, sinus pressures dropped to a mean of 15 mm Hg (6–33 mm Hg).

**Sinus Pressure Gradient**
The mean pressure gradient reported in 18 studies was 18.5 mm Hg (3–50 mm Hg, n = 185) [4–9, 12, 14, 15, 17–20, 22, 23]. After stenting, the mean gradient dropped to 3.2 mm Hg (0–23 mm Hg, n = 172), i.e. a reduction of 15.3 mm Hg in 14 studies [4–8, 12, 14, 18–23] (table 2).

**Stent Patency**
Over the follow-up period ranging from 2 to 108 months, all stents remained patent. There were two reports of in-stent thrombosis; both were cleared with antithrombotic treatment [5].

**Antithrombotic Regimen**
The most commonly reported regimen among the studies covered in this review consists of a dual antiplatelet therapy (aspirin and clopidogrel) for 3–5 days prior to treatment, heparin during treatment, dual antiplatelet therapy for 3–6 months following treatment, followed by aspirin for 1 year or more [6, 7, 12–14]. One study used only a single antiplatelet drug (clopidogrel) [9], and others used warfarin for 8 weeks followed by aspirin for 6 months or more [4, 5, 16].
### Table 2. Objective mechanical and imaging findings

<table>
<thead>
<tr>
<th>First author</th>
<th>Cases, n</th>
<th>Mean BMI (range)</th>
<th>Type of stenosis</th>
<th>CSF opening pressure, cm H₂O</th>
<th>Mean pressure gradient, mm Hg</th>
<th>Retreatments, n</th>
<th>Sinus pressure, mm Hg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>before</td>
<td>after</td>
<td>before</td>
<td>after</td>
</tr>
<tr>
<td>Ahmed [12], 2011</td>
<td>52</td>
<td>&gt;30 in 47 cases</td>
<td>EX: 11, IN: 17, GR: 24</td>
<td>32.9 (25–55) NR in 4</td>
<td>4/6 retreatments 23.8 (17–31)</td>
<td>19.1 (4–41)</td>
<td>0.6 (0–14)</td>
</tr>
<tr>
<td>Albuquerque [13], 2011</td>
<td>18</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>0</td>
<td>NR</td>
</tr>
<tr>
<td>Arac [20], 2009</td>
<td>1</td>
<td>29</td>
<td>CB</td>
<td>31</td>
<td>NR</td>
<td>14</td>
<td>2</td>
</tr>
<tr>
<td>Bussière [14], 2010</td>
<td>10</td>
<td>35.9 (27–47)</td>
<td>NR only range is given (25–50)</td>
<td>NR</td>
<td>28.25 (17–31)</td>
<td>11.25 (2–23)</td>
<td>NR</td>
</tr>
<tr>
<td>Donnet [9], 2008</td>
<td>10</td>
<td>27.3 (22–37)</td>
<td>NR</td>
<td>40.2 (29–59)</td>
<td>19 (9–19)</td>
<td>19.1 (12–34)</td>
<td>NR</td>
</tr>
<tr>
<td>Fields [6], 2012</td>
<td>15</td>
<td>39 (30–73)</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>24 (13–40)</td>
<td>4 (0–9)</td>
</tr>
<tr>
<td>He [10], 2012</td>
<td>12</td>
<td>36.9 (29–45)</td>
<td>NR</td>
<td>33.7 (25–46)</td>
<td>NR</td>
<td>18.9 (8–37)</td>
<td>5.75 (2–15)</td>
</tr>
<tr>
<td>Higgins [5], 2003</td>
<td>1</td>
<td>30.1</td>
<td>CB</td>
<td>35</td>
<td>13.7</td>
<td>18</td>
<td>3</td>
</tr>
<tr>
<td>Khalia [21], 2010</td>
<td>22</td>
<td>38.2 (23–61)</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>18 patients with data 13.3 (3–40)</td>
<td>18 patients with data 1.7 (0–7)</td>
</tr>
<tr>
<td>Kumpe [7], 2012</td>
<td>18</td>
<td>31.6 (22.6–38)</td>
<td>NR</td>
<td>39.6 (25–73) NR in 4</td>
<td>NR</td>
<td>21.4 (4–39)</td>
<td>2.6 (0–7)</td>
</tr>
<tr>
<td>Lazzaro [19], 2012</td>
<td>3</td>
<td>39.7 (31.5–47.7)</td>
<td>1 CB, 1 EX, 1 IN</td>
<td>2 reported, &gt;44 and 60</td>
<td>NR</td>
<td>32 (30–36)</td>
<td>3.7 (1–5)</td>
</tr>
<tr>
<td>Ogungbo [15], 2003</td>
<td>1</td>
<td>NR</td>
<td>CB</td>
<td>40</td>
<td>26</td>
<td>25</td>
<td>NR</td>
</tr>
<tr>
<td>Owler [18], 2003</td>
<td>4</td>
<td>30 (23–38)</td>
<td>NR</td>
<td>3 reported, 39 (30–48)</td>
<td>3 reported, 15 (15–16)</td>
<td>19 (12–25)</td>
<td>0.25 (0–1)</td>
</tr>
<tr>
<td>Paquet [17], 2008</td>
<td>1</td>
<td>NR</td>
<td>NR</td>
<td>30</td>
<td>NR</td>
<td>15</td>
<td>NR</td>
</tr>
<tr>
<td>Rajpal [16], 2005</td>
<td>1</td>
<td>26.9</td>
<td>CB</td>
<td>37</td>
<td>NR</td>
<td>25</td>
<td>NR</td>
</tr>
<tr>
<td>Radvany [8], 2013</td>
<td>12</td>
<td>32.6 (27.3–45.7)</td>
<td>NR</td>
<td>39.4 (29–55)</td>
<td>NR</td>
<td>12.4 (5–28)</td>
<td>1.27 (0–4)</td>
</tr>
<tr>
<td>Teleb [23], 2012</td>
<td>1</td>
<td>28</td>
<td>EX</td>
<td>48</td>
<td>NR</td>
<td>26</td>
<td>0</td>
</tr>
<tr>
<td>Zheng [22], 2010</td>
<td>1</td>
<td>26.1</td>
<td>IN, GR</td>
<td>40</td>
<td>14.5</td>
<td>12</td>
<td>0</td>
</tr>
</tbody>
</table>

Before and after treatment significance: paired t test <0.05 (0.002) paired t test <0.05 (0.0001) paired t test =0.05 (0.0001)

NR = Not reported; IN = intrinsic; GR = arachnoid granulation; EX = extrinsic (smooth gradual narrowing/tapered stenosis); CB = combined intrinsic and extrinsic. a Review of imaging, the type of stenosis was not reported. b Case series presented in abstract form at the 2010 Annual Meeting of the American Academy of Neurology, Poster P05.284.
**Types of Stenosis**

The described type of venous stenosis associated with IIH is extrinsic, intrinsic or a combination [24]. Ironically, Farb et al. [24] described this before most of the reported case series, yet only few studies comment on this subject although most of them refer to the article of Farb’s group. Of all series and reports, only Ahmed et al. [12] and Zheng et al. [22] report on an intrinsic arachnoid granulation. For case series or reports where imaging was available, the authors classified the type of stenosis (table 2).

**Technical and Procedural Aspects**

Most procedures reported in case series were performed under general anesthesia. Interestingly, Kumpe et al. [7] reported pressure with and without general anesthesia and noticed that 11 of 13 patients, who had pressures measured with and without anesthesia, had lower pressures under general anesthesia. The median and mean pressures were 21.1 and 21.5 mm Hg before and 10 and 13.7 mm Hg after the procedure, respectively. Preprocedure antiplatelet regimens were different as discussed above.

Below, the general treatment steps are described; however, every case series differed slightly. Vascular access is achieved using a 6- to 9-French-long sheath placed into the common femoral vein. After achieving access, a heparin bolus is administered followed by continuous infusion to maintain a clotting time of 2.5–3.5 times the baseline value throughout the duration of the procedure [7, 12, 13]. The sheath and a guide catheter are advanced over a wire to the jugular bulb. A microcatheter over a microwire is advanced from the jugular bulb to the superior sagittal sinus, and pressures are measured after withdrawing the microwire and attaching the microcatheter to a manometer, which measures pressure in millimeter of mercury. The microcatheter is withdrawn to the prestenotic transverse sinus segment and eventually to the poststenotic sigmoid sinus, and a pressure gradient is obtained across the stenotic area. This is repeated on the contralateral side by crossing the torcular and advancing the microwire and microcatheter to the contralateral jugular bulb then to the sigmoid sinus and to the transverse sinus. Again, the microwire is withdrawn and pressures are measured at the desired areas.

Once pressures are obtained, the microwire is advanced to the contralateral distal transverse sinus or superior sagittal sinus, and the microcatheter is exchanged for a stent. If tracking of the stent is difficult, a larger buddy wire can be used, the large guide catheter can be advanced past the stenosis to allow tracking of the stent, or the microwire can be exchanged for a stiffer microwire.

Once the stent is deployed and if a stenosis existed, a balloon is tracked to the area of stenosis and balloon angioplasty is performed to expand the stent. When satisfactory stenting is achieved, the microcatheter and microwire are reintroduced and pressures are obtained again to document poststenting pressures. Balloon angioplasty can be performed first, but all steps are similar except when a balloon is used instead of a stent (see fig. 1 for procedure steps).

**Complications**

In the 207 treated patients, only three major complications directly related to stent placement occurred: 1 case of vein perforation leading to subdural hematoma [12], 1 case in which a retroperitoneal hematoma developed but did not require treatment [13], and 1 case of transient contrast extravasation [14]. Other indirectly related complications included allergies to drugs administered prior to surgery (aspirin or clopidogrel), allergies to anesthesia, deep venous thrombosis, and mild transient headache lasting for a few weeks possibly due to dural stretching from the placed stent. There was one report of subdural, subarachnoid, and intracerebral bleeding during an emergency treatment for IIH but on the side contralateral to the stent placement [12].
Retreatment

Retreatment rates ranged from 0 to 33% [9, 21]. Six articles report retreatment in a total of 22 of 207 (10.6%) patients undergoing further treatment. Kumpe et al. [7] reported that 1 of 18 patients needed retreatment. Fields et al. [6] did not report retreatment, but 2 of 16 patients needed a ventriculoperitoneal shunt and another 2 of 16 underwent bilateral stenting during one session. This gives a rate of 4 of 16 (25%) patients who needed extra treatment. Another large case series had a retreatment rate of 12% (6 of 52 patients) [12]. All 6 patients showed recurrence due to restenosis and improved after retreatment (table 2).

Overall Clinical Outcome

Of the 207 treated patients, 181 showed improvement or complete resolution of symptoms, 27 reported no change of symptoms, 1 reported worsening of symptoms, and 3 patients were lost to long-term follow-up. The follow-up time span ranged from 2 months...
to 9 years. Most patients who still had symptoms reported having mild headaches that were manageable with medications. Stenting had an overall symptom improvement rate of 87%.

Discussion

Clinical Reasoning – Symptoms and Results

From the systematic analysis above, the published case series are in general consistent. Papilledema resolving in most patients is a consistent finding in the case series. Pulsatile tinnitus or other head noise was not reported in most case series, although it is one of the most consistent symptoms in IIH presenting in 60% of patients [25]. However, when pulsatile tinnitus was addressed, it showed resolution. Lastly, all pressure gradients had a significant change and resolution of pressure gradient to a normal gradient below 5 mm Hg [6, 7, 12, 26]. Our Student t test was statistically significant for a change in pressure gradient and venous sinus pressure (table 2).

The most frequently reported symptom, although not described in an objective way except in three studies, is resolution of headache [7, 8, 27]. Most case series report improvement but not complete resolution in most patients [5–7, 12, 13]. A recently published case series even reported that 10 of 12 female patients still had headaches despite resolution of papilledema [7]. Another, series only reported improvement in headaches, but did not mention the type or degree of symptom resolution [13]. This is in line with the literature that reports the coexistence of IIH with migraines and chronic daily headaches [28–32]. In addition, IIH patients have been reported to have allodynia and to be very sensitive to all types of pain [33]. Therefore, it is imperative to classify the type of headache before and after relief of ICP.

The overall picture is that objective findings tend to resolve but subjective findings, most notably headaches, show improvement but do not resolve. Keeping our results and those of others in mind, we do not recommend endovascular treatment of patients who suffer only from headache, unless it is disabling and improvement would warrant the risks of the procedure.

Pathophysiology and Imaging

Although our systematic analysis was not about pathophysiology and imaging, we believe that it is important to discuss it, as it may dictate which patients may benefit from this treatment modality. The annual incidence of IIH is between 0.9 and 1.07 per 100,000 inhabitants in the US and 15–19 cases per 100,000 in overweight women between the ages of 20–44 years [34, 35]. Cerebral sinus stenosis may be present in 30–93% of patients with IIH [2, 24, 36, 37]. The more worrisome issue concerning imaging is that stenosis can be overlooked as a normal variant due to granulation, artifact, or actually a normal variant. Higgins et al. [36] reanalyzed 20 IIH patients, whose magnetic resonance venograms were initially read as normal, specifically looking for signal dropout and comparing them to 40 controls without headaches. Thirteen of the 20 IIH patients had bilateral transverse sinus flow gaps compared to none of the 40 controls, giving a rate of 65 versus 0%, respectively [38]. Currently, it is well accepted that most IIH patients undergo transverse sinus stenosis [39]. This means that most patients do not need aggressive surgical treatment, and stenoses have probably no influence on the outcome of IIH [39].

Aside from different and subjective interpretive standards, temporary resolution of venous stenosis can occur after CSF drainage [40]. Therefore, we recommend venography with manometry even in cases where imaging was read as normal in severe refractory or fulminant cases.
Procedure and Complications

Technical success was achieved in more than 95% of the patients. The exception was a stent that could not be tracked to the appropriate position in the sinus. There were three major complications related to the procedure giving an acceptable major complication rate of 1.5%. Possible risk associated with endovascular treatment includes the risk of infection, bleeding, venous damage from catheters or wire, venous thrombosis, emboli and subdural hematoma.

In-stent thrombosis associated with venous sinus stenting is low. Over the follow-up period of 2–108 months, there were 2 reported cases of in-stent thrombosis, with a rate of 1.6%. The 2 cases of in-stent thrombosis which were successfully treated occurred in patients receiving treatment of warfarin following the procedure [5].

This rate is similar to other rates of in-stent thrombosis when stenting veins in nonthrombotic patients. Ludyga et al. [41], when stenting for cerebrospinal venous insufficiency as a treatment for multiple sclerosis, reported two incidents of in-stent thrombosis out of 152 cases, with a rate of 1.2%. Ye et al. [42] reported a primary patency rate of 98.7% (n = 205) after 4 years of follow-up when treating nonthrombotic iliac vein compression lesions. The patency rate after treatment of rare thrombotic events was 100%. The most commonly reported regimens among the studies covered in this review consist of dual antiplatelet therapy (aspirin and clopidogrel) for 3–5 days prior to treatment, heparin during treatment, dual antiplatelet therapy for 3–6 months following treatment, followed by aspirin for 1 year or more [6, 7, 12–14]. One study used only a single antiplatelet drug (clopidogrel) [9], and others used warfarin for 8 weeks followed by aspirin for 6 months or more [4, 5, 16].

Types of Stenoses

Evidence also points to obstruction of venous outflow due to causes other than an elevated ICP. One case series showed evidence of arachnoid granulations or septae possibly causing sinus stenosis [12]. Another case series reported on a case of stenosis caused by an obstruction consistent with fat deposits, and 2 cases of patients with functioning shunts and existent stenoses [18]. In addition, the magnetic resonance venograms studies by Farb et al. [24, 43] report on these different types of stenoses. Unfortunately, few studies report on this subject; however, it could possibly affect the result of the endovascular treatment, as intrinsic stenosis can be the initial cause in a particular patient, which could possibly have a positive influence in this subset of patients.

Retreatment

The different rates could be due to longer follow-up periods as well as some case series having refractory patients treated with ventriculoperitoneal shunts as opposed to endovascular retreatment. Although the numbers are too small to show significance, a higher pressure gradient, more complete gradient resolution, and unilateral as opposed to bilateral stenosis seemed to favor the need for only one treatment.

Other Treatment and Overall Analysis

Other invasive treatment for IIH includes optic nerve sheath fenestration and ventriculoperitoneal shunt/lumboperitoneal shunt placement. Shunts have good initial results but their long-term efficacy and high rate of revision is undesirable. Shunts for IIH have an 80% revision rate at 3 years, with severe headache recurrence in 48% of patients despite functioning [44]. Optic nerve sheath fenestration has a procedural complication rate ranging from 23 to 40%, which includes blindness [45–48].

Currently, sinus venous stenting for IIH seems safer and as efficacious as ventriculoperitoneal shunting as well as optic nerve fenestration as evidenced by our analysis. However,
this applies only to the initial procedural risk and short-term follow-up. Larger prospective trials with long-term follow-up are required to effectively quantify the risks and benefits of stenting in refractory IIH patients.

The time frame could skew the results towards a more favorable result as there are fewer individuals with long-term follow-up who could possibly have more complications, than those with shorter follow-up periods. Currently, there is only one phase 1 prospective safety trial (funded by the NIH and published by the Cornell University, New York, N.Y., USA), with the aim of enrolling 20 patients over 24 months [49]. In the future, a multicenter study is needed to fully evaluate the efficacy of venous sinus stenting for IIH.

We have suggested a criterion for patient selection in table 3. Endovascular management of IIH patients should be considered in patients who have disabling symptoms after maximal medical therapy or fulminant cases with dural sinus stenosis. These are only proposed criteria based on our local experience and published literature which require prospective registries and trials for validation. However, there is still much debate about the use of stenting in IIH, especially in the literature on neuro-ophthalmology, as evidenced by recent point-counterpoint article [27].

Table 3. Proposed criteria for cerebral venous stenting

<table>
<thead>
<tr>
<th>Major criteria (all required for qualification)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Failed maximal medical therapy or fulminant course refractory to medical treatment with rapidly worsening vision</td>
</tr>
<tr>
<td>Presence of pressure gradient across the stenosis ≥8 mm Hg</td>
</tr>
<tr>
<td>Pressure ≥22 mm Hg (30 cm H₂O)</td>
</tr>
<tr>
<td>Visual changes, papilledema, or other focal objective neurological symptoms, headaches only if severely disabling</td>
</tr>
<tr>
<td>No contraindications to dual antiplatelet therapy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Minor criteria (one required for qualification)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intolerance to repeated lumbar puncture or lumbar drain</td>
</tr>
<tr>
<td>Diagnosis of dural sinus stenosis ≥50% on CT or MR venography</td>
</tr>
<tr>
<td>Failed surgical shunting procedure or failed optic nerve fenestration</td>
</tr>
<tr>
<td>Pulsatility seen on manometry which is attenuated after stenosis</td>
</tr>
<tr>
<td>Patient preference</td>
</tr>
</tbody>
</table>

Conclusion

Endovascular management of dural sinus stenosis appears technically feasible and safe. It is clinically efficacious in patients with IIH who failed medical and surgical therapy with dural sinus stenosis. It should be considered after failing maximal medical therapy. Lastly, we suggest creation of a formal multicenter clinical registry to prospectively measure safety and long-term efficacy of the procedure. Our proposed registry name is STRIPE (Stenting To Relieve Intracranial Pressure Endovascularly).

Acknowledgement

This publication was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Number 8UL1TR000055. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.
Disclosure Statement

The authors have no competing interests. There was no external funding for this review.

References


